Active, Not Recruiting
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
NCT02485015
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, +5 more
- Locations
-
Not specified